US2006194739A1PendingUtilityA1
Nociceptin-based analgesics
Individually held — no corporate assignee on recordPriority: Oct 9, 2001Filed: Apr 11, 2006Published: Aug 31, 2006
Est. expiryOct 9, 2021(expired)· nominal 20-yr term from priority
Inventors:Amrit K. Judd
A61K 38/00C07K 14/665
64
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to a family of hexapeptide compounds exhibiting activity with regard to the ORL-1 receptor. The compounds share a general formula of Arg-Tyr-Tyr-Arg-Trp-Arg, and may be constructed having modifications or substitutions at any position, and may include modifications of the amino- and carboxy-termini of the hexapeptide. These compounds include agents exhibiting agonist activity and antagonist activity when exposed to the human ORL-1 receptor. As such, the hexapeptides may be useful as analgesics, anxiolytics, diuretics, and anti-cancer agents.
Claims
exact text as granted — not AI-modified1 . A hexapeptide of the formula:
Arg-Xaa-Tyr-Arg-Trp-Arg (SEQ ID NO: 17), wherein the hexapeptide binds with the ORL-1 receptor, wherein Xaa is selected from the group consisting of natural amino acids, D-amino acids, non-natural amino acids, modified natural amino acids, and amino acid analogs.
2 . (canceled)
3 . (canceled)
4 . (canceled)
5 . The hexapeptide of claim 1 , having the formula of SEQ ID NO: 1.
6 . The hexapeptide of claim 1 , having the formula of SEQ ID NO: 2.
7 . The hexapeptide of claim 1 , having the formula of SEQ ID NO: 3.
8 . The hexapeptide of claim 1 , having the formula of SEQ ID NO: 4.
9 . The hexapeptide of claim 1 , having the formula of SEQ ID NO: 6.
10 . (canceled)
11 . (canceled)
12 . The hexapeptide of claim 1 , having the formula of SEQ ID NO: 5.
13 . The hexapeptide of claim 1 , having the formula of SEQ ID NO: 7.
14 . The hexapeptide of claim 1 , having the formula of SEQ ID NO: 23.
15 . (canceled)
16 . (canceled)
17 . (canceled)
18 . (canceled)
19 . (canceled)
20 . (canceled)
21 . A hexapeptide of the formula:
Arg-Tyr-Xaa-Arg-Trp-Arg (SEQ ID NO: 18), wherein the hexapeptide binds with the ORL-1 receptor, wherein Xaa is selected from the group consisting of natural amino acids, D-amino acids, non-natural amino acids, modified natural amino acids, and amino acid analogs.
22 . (canceled)
23 . (canceled)
24 . (canceled)
25 . The hexapeptide of claim 21 , having the formula of SEQ ID NO: 12.
26 . The hexapeptide of claim 21 , having the formula of SEQ ID NO: 13.
27 . The hexapeptide of claim 21 , having the formula of SEQ ID NO: 20.
28 . The hexapeptide of claim 21 , having the formula of SEQ ID NO: 21.
29 . The hexapeptide of claim 21 , having the formula of SEQ ID NO: 16.
30 . The hexapeptide of claim 21 , having the formula of SEQ ID NO: 22.
31 . The hexapeptide of claim 21 , wherein Xaa is a modified Tyr amino acid molecule.
32 . The hexapeptide of claim 31 , wherein Xaa is Tyr (2, 6 di-Me) (SEQ ID NO: 15).
33 . (canceled)
34 . (canceled)
35 . (canceled)
36 . (canceled)
37 . (canceled)
38 . (canceled)
39 . (canceled)
40 . (canceled)
41 . (canceled)
42 . (canceled)
43 . (canceled)
44 . (canceled)
45 . (canceled)
46 . (canceled)
47 . (canceled)
48 . (canceled)
49 . (canceled)
50 . (canceled)
51 . (canceled)
52 . A hexapeptide of the formula:
Arg-Tyr-Tyr-Arg-Xaa-Arg (SEQ ID NO: 27), wherein the hexapeptide binds with the ORL-1 receptor, wherein Xaa is selected from the group consisting of natural amino acids, D-amino acids, non-natural amino acids, modified natural amino acids, and amino acid analogs.
53 . (canceled)
54 . (canceled)
55 . (canceled)
56 . (canceled)
57 . (canceled)
58 . (canceled)
59 . (canceled)
60 . (canceled)
61 . (canceled)
62 . (canceled)
63 . (canceled)
64 . (canceled)
65 . (canceled)
66 . (canceled)
67 . (canceled)Join the waitlist — get patent alerts
Track US2006194739A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.